| Name | Western Drug #4 |
|---|---|
| Organization Name | Texoma Medical Services Inc |
| Location | 2008 W Gary Blvd, Clinton, Oklahoma 73601 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (580) 323-1136 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Inflammation is a Catch-22: the body needs it to eliminate invasive organisms and foreign irritants, but excessive inflammation can harm healthy cells, contributing to aging and sometimes leading to organ failure and death. Researchers at University of California, San Diego School of Medicine have discovered that a protein known as p62 acts as a molecular brake to keep inflammation in check and avoid collateral damage.
Scientists have discovered a protein which could improve the success rate of the tumour shrinking drug paclitaxel, in the treatment of ovarian cancer, a study reveals in Cancer Cell.
A researcher from Plymouth University Peninsula Schools of Medicine and Dentistry has received an award of - 94,365 (Sterling) from the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), for a pilot study to develop the lab-based creation of a type of mouse cell which could be used in place of the live animals for research related to infectious and allergic lung conditions.
A new clinical study has shown that imatinib mesylate (Gleevec) has activity in AIDS-related Kaposi's sarcoma (KS). Imatinib inhibits important pathways that spur cancer growth, resulting in the regression of KS tumors within 4 weeks in some patients. The study will be published November 30 in the Journal of Clinical Oncology (JCO).
Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.
› Verified 1 days ago
| NPI Number | 1023273562 |
| Organization Name | TEXOMA MEDICAL SERVICES, INC. |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 2008 W Gary Blvd, Clinton, OK 73601 |
| Phone Number | 580-323-1136 |
News Archive
Inflammation is a Catch-22: the body needs it to eliminate invasive organisms and foreign irritants, but excessive inflammation can harm healthy cells, contributing to aging and sometimes leading to organ failure and death. Researchers at University of California, San Diego School of Medicine have discovered that a protein known as p62 acts as a molecular brake to keep inflammation in check and avoid collateral damage.
Scientists have discovered a protein which could improve the success rate of the tumour shrinking drug paclitaxel, in the treatment of ovarian cancer, a study reveals in Cancer Cell.
A researcher from Plymouth University Peninsula Schools of Medicine and Dentistry has received an award of - 94,365 (Sterling) from the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), for a pilot study to develop the lab-based creation of a type of mouse cell which could be used in place of the live animals for research related to infectious and allergic lung conditions.
A new clinical study has shown that imatinib mesylate (Gleevec) has activity in AIDS-related Kaposi's sarcoma (KS). Imatinib inhibits important pathways that spur cancer growth, resulting in the regression of KS tumors within 4 weeks in some patients. The study will be published November 30 in the Journal of Clinical Oncology (JCO).
Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.
› Verified 1 days ago
| NPI Number | 1982668778 |
| Organization Name | TEXOMA MEDICAL SERVICES INC |
| Doing Business As | WESTERN DRUG #4 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 2008 W Gary Blvd, Clinton, OK 73601 |
| Phone Number | 580-323-1136 |
News Archive
Inflammation is a Catch-22: the body needs it to eliminate invasive organisms and foreign irritants, but excessive inflammation can harm healthy cells, contributing to aging and sometimes leading to organ failure and death. Researchers at University of California, San Diego School of Medicine have discovered that a protein known as p62 acts as a molecular brake to keep inflammation in check and avoid collateral damage.
Scientists have discovered a protein which could improve the success rate of the tumour shrinking drug paclitaxel, in the treatment of ovarian cancer, a study reveals in Cancer Cell.
A researcher from Plymouth University Peninsula Schools of Medicine and Dentistry has received an award of - 94,365 (Sterling) from the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), for a pilot study to develop the lab-based creation of a type of mouse cell which could be used in place of the live animals for research related to infectious and allergic lung conditions.
A new clinical study has shown that imatinib mesylate (Gleevec) has activity in AIDS-related Kaposi's sarcoma (KS). Imatinib inhibits important pathways that spur cancer growth, resulting in the regression of KS tumors within 4 weeks in some patients. The study will be published November 30 in the Journal of Clinical Oncology (JCO).
Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.
› Verified 1 days ago
News Archive
Inflammation is a Catch-22: the body needs it to eliminate invasive organisms and foreign irritants, but excessive inflammation can harm healthy cells, contributing to aging and sometimes leading to organ failure and death. Researchers at University of California, San Diego School of Medicine have discovered that a protein known as p62 acts as a molecular brake to keep inflammation in check and avoid collateral damage.
Scientists have discovered a protein which could improve the success rate of the tumour shrinking drug paclitaxel, in the treatment of ovarian cancer, a study reveals in Cancer Cell.
A researcher from Plymouth University Peninsula Schools of Medicine and Dentistry has received an award of - 94,365 (Sterling) from the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), for a pilot study to develop the lab-based creation of a type of mouse cell which could be used in place of the live animals for research related to infectious and allergic lung conditions.
A new clinical study has shown that imatinib mesylate (Gleevec) has activity in AIDS-related Kaposi's sarcoma (KS). Imatinib inhibits important pathways that spur cancer growth, resulting in the regression of KS tumors within 4 weeks in some patients. The study will be published November 30 in the Journal of Clinical Oncology (JCO).
Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.
› Verified 1 days ago
Priority Home Medical Equipment Llc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 517 S 30th St, Clinton, Oklahoma 73601 Phone: (580) 275-2632 | |
Lincare Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 553 S 30th St, Clinton, Oklahoma 73601 Phone: (580) 323-1377 | |
Salisbury Pharmacy Type: Durable Medical Equipment & Medical Supplies Supplier Location: 815 Frisco Ave, Clinton, Oklahoma 73601 Phone: (580) 323-1244 | |
Western Drug #4 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2008 W Gary Blvd, Clinton, Oklahoma 73601 Phone: (580) 323-1136 | |